9/2/2023 0 Comments Pet28a vector snapgene![]() aeruginosa are lipopolysaccharides (LPS) and outer membrane proteins (OMPs) because of their accessibility on the pathogen surface. Major antigenic surface-associated components of P. aeruginosa hence suitable as a vaccine targets. aeruginosa have several antigenic components that are involved in the development of immunity in the host against P. Extracellular secretory products and membrane of P. Recently, there is developing attention in the various bacterial components like virulence factors for the development of vaccines and other therapies 15. Damage to the first line of defense, such as the skin or the mucous membranes, enables the colonizing bacteria to enter the bloodstream and cause septicemia 14. aeruginosa against most of the antibiotics 13. aeruginosa infection is higher as compared to other Gram-negative pathogens 12 due to the emergence of resistance in P. Mortality rate in bacteremia caused by P. aeruginosa causes opportunistic nosocomial infection such as bacteremia, pneumonia and septicemia 11. In spite of the use of different mechanisms, to cure the ESKAPE pathogen, there is not any permanent treatment available. Different molecules such as herbal compounds 1, 2, secondary metabolites 1, 3, 4 nanomaterial 5, 6 and in-silico designed drug 7, 8, 9, 10 are used to find a suitable alternative to the current antibiotics used against ESKAPE pathogen. Hospital-based surveillance studies as well as Infectious Diseases Society of America have begun to refer nosocomial pathogens as ESKAPE pathogens that include Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species. aeruginosa with host and infection caused by P. Therefore, the designed construct VT4 may be studied to control the interaction of P. The final vaccine VT-4 construct was in-silico cloned in pET28a. The final selected VT4 construct was docked with TLR4/MD2 complex and confirmed by molecular dynamics simulation studies. Selected chimeric vaccine constructs (VT1, VT3, and VT4) were further shortlisted by their docking score with different HLA alleles. The designed vaccine constructs (VT1, VT2, VT3, and VT4) were analyzed by their physiochemical properties using different tools. ![]() All the epitopes, adjuvants and PADRE sequence were joined by linkers. Immune-modulating adjuvants and PADRE (Pan HLA-DR epitopes) sequence were added with epitopes sequence to enhance the immunogenicity. Immunogenic peptides were used to design a multi-epitope vaccine construct. The selected epitopes were shortlisted based on their allergenicity, toxicity potentials, solubility, and hydrophilicity analysis. Reverse vaccinology approach was used to identify antigenic and immunogenic MHC class I, MHC class II and B cell epitopes present in the selected OMPs that can enhance T cell and B cell mediated immunogenicity. aeruginosa were selected based on the basis of hydrophilicity, non-secretory nature, low transmembrane helix (<1), essentiality, virulence, pathway association, antigenic, and protein-protein network analysis. In these proteomes, fifteen outer membrane proteins (OMPs) of P. aeruginosa, a total of twenty unique non-redundant proteomes were selected. Using comparative subtractive proteomic analysis of 1,191 proteomes of P. aeruginosa with the help of comparative proteomics and reverse vaccinology approaches. In the present study, we have designed a chimeric vaccine against P. Therefore, it is important to find a therapeutic for this pathogen. Multidrug-resistant Pseudomonas aeruginosa is one of the worldwide health problems involved in elevated mortality and morbidity.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |